Joan Brugge

Joan Brugge is a cell biologist who specializes in the field of cancer research. She has been recognized for many aspects of her research, including her explorations into the Rous sarcoma virus, extracellular matrix adhesion, and epithelial tumor progression in breast cancer.[1][2] Brugge serves as the Louise Foote Pfeiffer Professor of Cell Biology and the Director of the Ludwig Center at Harvard Medical School, where she also served as the Chair of the Department of Cell Biology from 2004 to 2014.[3][4]

Education

Brugge originally intended on pursuing a career as a mathematics instructor. While she was attending Northwestern University as an undergraduate student, her sister developed a brain tumor. This event sparked a newfound passion for biology and specifically cancer research. While Brugge was completing her undergraduate degree in biology, she became interested in tumor virology, which refers to the study of how viruses can affect and in some cases produce cancerous cells.[5][6] This focus led her to the Baylor College of Medicine in Houston, Texas, which housed one of the only virology programs in the country at the time.[1] Brugge graduated with her doctorate degree in virology in 1975.[7]

Professional career

After the completion of her doctorate degree, Brugge joined Dr. Ray Erickson at the University of Colorado for her postdoctorate work. It was there that she discovered a protein that was formed from both the viral and cellular forms of the Src gene.[5] This was a major breakthrough in cancer research, since it proved that genes that cause cells to become cancerous originate from normal cellular genes.[1]

In 1979, Brugge took an assistant professor position at the State University of New York (SUNY) at Stony Brook, eventually becoming a Professor of Microbiology. She continued her studies on the Rous sarcoma virus (RSV) that she had discovered in her postdoctorate work. Much of her research centered on finding the role of pp60, which is the protein that is coded for by RSV.[8][9] Brugge then moved on to the same position at the University of Pennsylvania in 1989.[7] During this time, she was also named an Investigator for the Howard Hughes Medical Institute, which is an assembly of medical scientists and researchers that advances biomedical research for the benefit of the general public.[10][11]

In 1992, Brugge joined ARIAD Pharmaceuticals in Cambridge, Massachusetts as its Scientific Director.[7] ARIAD primarily focuses on making drugs for the treatment of cancers with limited treatment options.[12] After five years in industry, however, Brugge chose to return to the academic world in order to place a bigger focus on her own research. She took a position as a Professor in the Department of Cell Biology at Harvard Medical School in 1997, and she has been the Chair of the department since 2003. Brugge has redirected her most recent research efforts because, in her own words, "we were kind of lured into areas that were pretty far from cancer, so I really wanted to go back to cancer."[5] Her lab focuses on the metastatic growth of epithelial cell tumors, primarily in the arena of breast cancer.[3][10][2][13][14][15]

Awards and recognitions

Brugge is a member of the American Society of Cell Biologists (ASCB). She received the society's annual Women in Cell Biology Award in 2001 and was elected to serve on the governing Council in 2008.[1][16] Brugge was awarded an American Cancer Society Research Professorship in 2001, and her work has been funded by the Breast Cancer Research Foundation.[10][17] Some of Brugge's other recognitions include:

Selected publications

References

  1. 1 2 3 4 Allan, S. "At the Leading Edge of Cancer Research: An Interview with Joan Brugge". Disease Models & Mechanisms 4.1 (2010): 9-11.
  2. 1 2 3 "Joan S. Brugge, PhD | Class of 2014". American Association for Cancer Research. AACR.
  3. 1 2 "Joan S. Brugge, PhD". Dana-Farber/Harvard Cancer Center. NCICCC.
  4. ↑ "Joan Brugge". Harvard Medical School - Department of Cell Biology. The President and Fellows of Harvard College.
  5. 1 2 3 "Joan Brugge." American Society for Cell Biology 1 (3 Aug. 2009): Print.
  6. ↑ Javier, R. T., and J. S. Butel. "The History of Tumor Virology." Cancer Research 68.19 (2008): 7693-706.
  7. 1 2 3 "Joan Brugge". The Brugge Lab. The President and Fellows of Harvard College.
  8. ↑ Brugge, JS, A Lustig, and A Messer. "Changes in the Pattern of Expression of Pp60c-src in Cerebellar Mutants of Mice." Journal of Neuroscience Research 18.4 (1987): 532-38.
  9. ↑ Brugge, JS, G. Jarosik, J Andersen, et al. "Expression of Rous Sarcoma Virus Transforming Protein Pp60v-src in Saccharomyces Cerevisiae Cells." Molecular and Cellular Biology 7.6 (1987): 2180-187.
  10. 1 2 3 "Joan S. Brugge, PhD". BCRF. The Breast Cancer Research Foundation.
  11. ↑ "About Us". Hhmi. Howard Hughes Medical Institute.
  12. ↑ "About ARIAD". ARIAD. ARIAD Pharmaceuticals, Inc.
  13. ↑ Worster, D. T., T. Schmelzle, N. L. Solimini, E. S. Lightcap, B. Millard, G. B. Mills, J. S. Brugge, and J. G. Albeck. "Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor P57Kip2." Science Signaling 5.214 (2012): Ra19.
  14. ↑ Muranen, Taru, Laura M. Selfors, Devin T. Worster, Marcin P. Iwanicki, Loling Song, Fabiana C. Morales, Sizhen Gao, Gordon B. Mills, and Joan S. Brugge. "Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells." Cancer Cell 21.2 (2012): 227-39.
  15. ↑ Wang, L., J. S. Brugge, and K. A. Janes. "PNAS Plus: Intersection of FOXO- and RUNX1-mediated Gene Expression Programs in Single Breast Epithelial Cells during Morphogenesis and Tumor Progression." Proceedings of the National Academy of Sciences 108.40 (2011): E803-812.
  16. ↑ "WICB Awards". The American Society for Cell Biology. ascb.
  17. ↑ American Cancer Society. "American Cancer Society Names Three Research Professors; Researchers Receive $400,000 Five-Year Grants". PR Newswire. UBM Plc.
This article is issued from Wikipedia - version of the Tuesday, November 24, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.